Please ensure Javascript is enabled for purposes of website accessibility

Why Clovis Oncology Shares Got a Bump This Week

By Jim Halley – Aug 27, 2021 at 11:37AM

Key Points

  • Clovis may be benefitting from a short-squeeze effort by retail investors.
  • The jump was surprising considering the company’s disappointing second-quarter numbers.
  • The company has one marketed drug, Rubraca.

Motley Fool Issues Rare “All In” Buy Alert

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares of the biotech that focuses on oncology drugs climbed more than 12% during the week.

What happened

Clovis Oncology (CLVS 1.76%) saw its shares climb more than 12% this week. The stock was as low as $4.07 last Friday, but closed the day at $4.24. It opened at $4.27 on Monday and rose to as high as $4.78 on Thursday. Over the past 52 weeks, it has been as high as $11.10 and as low as $4.06.

So what

The stock certainly wasn't buoyed by its fundamentals. It was coming off of disappointing second-quarter earnings. Clovis is a small-cap pharmaceutical company that focuses on oncology drugs, but sales of its only marketed drug, Rubraca, used to treat ovarian cancer, are down at the year's halfway point.

A patient holds a poodle while talking to a health worker.

Image source: Getty Images.

The company said that through six months, it had $74.8 million in revenue, down 9% year over year. The company has also lost $132.7 million in that time. That's down from the $191.5 million the company lost in the first six months of 2020, but that's because it has spent less on research and development.

So, why did the biotech stock rise? The stock has been heavily shorted and Reddit-influenced retail investors are buying the stock in hopes of a short squeeze. Basically, the plan is to boost the stock's price high enough that hedge funds and others shorting the stock will be forced to cover their positions, goosing the stock even higher. It makes sense -- rather than trying a short squeeze with a stock with a much larger market cap, Clovis' market cap of $537.58 million is easier to influence.

Now what

As anyone watching the market knows, short squeezes are not always effective. It's hard to get that excited about a stock with only one product that has had declining sales, but it's not all negative for Clovis.

First, the company has several trials underway to expand Rubraca's usage, possibly as a treatment for prostate cancer or for patients with solid tumors stemming from mutations in homologous recombination repair genes.

Second, the company's portfolio includes FAP-2286, which it is testing against solid tumors and it is working with Bristol Myers Squibb on a trial to test a combination of Clovis' lucitanib and Bristol's nivolumab in patients with advanced gynecological solid tumors.

Third, the company has blamed the COVID-19 pandemic for slowing sales, and if the pandemic ebbs, that would mean increased sales and optimism from investors for Clovis. In the long run, it's not a bad bet to see the stock going higher. Even with the recent run, it's a lot closer to its two-year low than its two-year high.

Jim Halley has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Bristol Myers Squibb. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Clovis Oncology Stock Quote
Clovis Oncology
CLVS
$0.35 (1.76%) $0.01
Bristol Myers Squibb Stock Quote
Bristol Myers Squibb
BMY
$79.24 (0.13%) $0.10

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
356%
 
S&P 500 Returns
118%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.